Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 621

2.

B cell depletion therapy in systemic lupus erythematosus: relationships among serum B lymphocyte stimulator levels, autoantibody profile and clinical response.

Cambridge G, Isenberg DA, Edwards JC, Leandro MJ, Migone TS, Teodorescu M, Stohl W.

Ann Rheum Dis. 2008 Jul;67(7):1011-6. Epub 2007 Oct 25.

PMID:
17962238
3.

Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis.

Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, Bodman-Smith M, Webster AD.

Arthritis Rheum. 2003 Aug;48(8):2146-54.

4.

Changes in macrophage function after rituximab treatment in patients with rheumatoid arthritis.

Toubi E, Kessel A, Slobodin G, Boulman N, Pavlotzky E, Zisman D, Rozenbaum M, Rosner I.

Ann Rheum Dis. 2007 Jun;66(6):818-20. Epub 2006 Dec 5.

5.

The effect of B-cell depletion therapy on serological evidence of B-cell and plasmablast activation in patients with rheumatoid arthritis over multiple cycles of rituximab treatment.

Cambridge G, Perry HC, Nogueira L, Serre G, Parsons HM, De La Torre I, Dickson MC, Leandro MJ, Edwards JC.

J Autoimmun. 2014 May;50:67-76. doi: 10.1016/j.jaut.2013.12.002. Epub 2013 Dec 22.

PMID:
24365380
6.

Reconstitution of peripheral blood B cells after depletion with rituximab in patients with rheumatoid arthritis.

Leandro MJ, Cambridge G, Ehrenstein MR, Edwards JC.

Arthritis Rheum. 2006 Feb;54(2):613-20.

7.

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

Cheema GS, Roschke V, Hilbert DM, Stohl W.

Arthritis Rheum. 2001 Jun;44(6):1313-9.

8.

Immunohistochemical analysis as a means to predict responsiveness to rituximab treatment.

Teng YK, Levarht EW, Hashemi M, Bajema IM, Toes RE, Huizinga TW, van Laar JM.

Arthritis Rheum. 2007 Dec;56(12):3909-18.

9.
10.

Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response.

Nakou M, Katsikas G, Sidiropoulos P, Bertsias G, Papadimitraki E, Raptopoulou A, Koutala H, Papadaki HA, Kritikos H, Boumpas DT.

Arthritis Res Ther. 2009;11(4):R131. doi: 10.1186/ar2798. Epub 2009 Aug 28.

11.

B lymphocyte stimulator protein-associated increase in circulating autoantibody levels may require CD4+ T cells: lessons from HIV-infected patients.

Stohl W, Cheema GS, Briggs WS, Xu D, Sosnovtseva S, Roschke V, Ferrara DE, Labat K, Sattler FR, Pierangeli SS, Hilbert DM.

Clin Immunol. 2002 Aug;104(2):115-22.

PMID:
12165272
12.

Local production of B lymphocyte stimulator protein and APRIL in arthritic joints of patients with inflammatory arthritis.

Tan SM, Xu D, Roschke V, Perry JW, Arkfeld DG, Ehresmann GR, Migone TS, Hilbert DM, Stohl W.

Arthritis Rheum. 2003 Apr;48(4):982-92.

13.

B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations.

Stohl W, Metyas S, Tan SM, Cheema GS, Oamar B, Xu D, Roschke V, Wu Y, Baker KP, Hilbert DM.

Arthritis Rheum. 2003 Dec;48(12):3475-86.

14.

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles.

Cambridge G, Leandro MJ, Teodorescu M, Manson J, Rahman A, Isenberg DA, Edwards JC.

Arthritis Rheum. 2006 Nov;54(11):3612-22.

15.

Apoptotic effect of rituximab on peripheral blood B cells in rheumatoid arthritis.

Szodoray P, Alex P, Dandapani V, Nakken B, Pesina J, Kim X, Wallis GL, Wilson PC, Jonsson R, Centola M.

Scand J Immunol. 2004 Jul-Aug;60(1-2):209-18.

16.

Raised levels of anti-glucose-6-phosphate isomerase IgG in serum and synovial fluid from patients with inflammatory arthritis.

Schaller M, Stohl W, Tan SM, Benoit VM, Hilbert DM, Ditzel HJ.

Ann Rheum Dis. 2005 May;64(5):743-9. Epub 2004 Sep 30.

17.

Repeated B lymphocyte depletion with rituximab in rheumatoid arthritis over 7 yrs.

Popa C, Leandro MJ, Cambridge G, Edwards JC.

Rheumatology (Oxford). 2007 Apr;46(4):626-30. Epub 2006 Dec 19.

18.

Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response.

Breedveld F, Agarwal S, Yin M, Ren S, Li NF, Shaw TM, Davies BE.

J Clin Pharmacol. 2007 Sep;47(9):1119-28.

PMID:
17766699
19.
20.

Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort.

Gottenberg JE, Miceli-Richard C, Ducot B, Goupille P, Combe B, Mariette X.

Arthritis Res Ther. 2009;11(4):R114. doi: 10.1186/ar2773. Epub 2009 Jul 23.

Items per page

Supplemental Content

Write to the Help Desk